

**Question for written answer E-004669/2020
to the Commission**

Rule 138

Bartosz Arłukowicz (PPE)

Subject: Cardiotoxicity of cancer treatment

Recent studies have shown that advances in cancer treatment have improved the survival rate of cancer patients, but also that they have increased morbidity and mortality due to the cardiotoxicity of cancer treatments. Cardiovascular diseases (heart failure, myocardial infarction, arrhythmia) are among the most common side effects. This is a result of cardiotoxicity, which is associated with the direct impact of cancer treatment on heart function. As indicated by the European Society of Cardiology, there is growing concern that side effects may lead to premature morbidity and death among survivors of cancer.

The interaction between cancer and cardiovascular diseases is a huge mental burden for patients and has a significant economic impact on EU health systems, indicating the need to fight diseases in a holistic approach.

In the light of the foregoing, can the Commission say:

1. How does it plan to promote research on co-morbidities and complications of cancer and cardiovascular diseases as part of Europe's Beating Cancer Plan?
2. How does it plan to address cardiovascular diseases and cancer-related complications as part of Europe's Beating Cancer Plan, with a view to strengthening integrated and multidisciplinary cancer care?